Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 2;22(1):7.
doi: 10.1007/s11864-020-00799-9.

Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Guillaume Grisay  1 , Julien Pierrard  1 , Caterina Confente  1 , Emmanuel Seront  2
Affiliations
Review

Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Guillaume Grisay et al. Curr Treat Options Oncol. .

Abstract

Immune checkpoint inhibitors have importantly improved the outcome of patients with urothelial carcinoma. Different immune checkpoint inhibitors are currently approved and used in first- and second-line setting. The multiple agents currently approved in these setting make the choice sometimes difficult for clinicians. Furthermore, only a minority of patients present drastic response and long-term benefit with current immunotherapy. In this review, we describe the current use of immunotherapy in urothelial carcinoma but we also highlight the new strategies of treatment involving immune checkpoint inhibitors; we describe the place of immunotherapy with chemotherapy, targeted agents, and anti-angiogenic agents, incorporating the recent results presented at ASCO 2020. This review explores also the different action mechanisms of immune checkpoint inhibitors and the molecular rational to evaluate these agents in other strategies, such as maintenance and salvage strategies. The new advances in biomarker development are also presented.

Keywords: Anti-angiogenic agents; Biomarkers; Combination therapy; Immune checkpoint inhibitors; Targeted therapy; Urothelial carcinoma.

PubMed Disclaimer

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. Jama. 2011;306(7):737–45. - PubMed - PMC - DOI
    1. Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, et al. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol. 2010;57(2):283–92. - PubMed - DOI
    1. Abern MR, et al. The characteristics of bladder cancer after radiotherapy for prostate cancer. In: Urologic Oncology: Seminars and Original Investigations: Elsevier; 2013.
    1. Pelucchi C, Bosetti C, Negri E, Malvezzi M, la Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol. 2006;3(6):327–40. - PubMed - DOI
    1. Amin MB, McKenney J, Paner GP, Hansel DE, Grignon DJ, Montironi R, et al. ICUD-EAU international consultation on bladder cancer 2012: pathology. Eur Urol. 2013;63(1):16–35. - PubMed - DOI

MeSH terms

LinkOut - more resources